Showing 6161-6170 of 7326 results for "".
- Ortho Dermatologics' Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ortho-dermatologics-psoriasis-drug-bryhali-performs-well-in-two-phase-3-trials/2457585/Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe plaque psoriasis, is effective and well-tolerated. Bryhali Lotion has a Prescription Drug
- Bellus Medical Now Part of Crown Laboratorieshttps://practicaldermatology.com/news/bellus-medical-now-part-of-crown-laboratories/2457590/Crown Laboratories, Inc. and Hildred Capital Partners, LLC have acquired Bellus Medical. Bellus’s non-invasive offerings include the SkinPen, a medical grade microneedling device used exclusively by healthcare professionals to improve the appearance of facial acne scars. It is the f
- Research Identifies Disparities in Outpatient Dermatologic Carehttps://practicaldermatology.com/news/research-identifies-disparities-in-outpatient-dermatologic-care/2457592/The odds of a black or Hispanic patient visiting an outpatient dermatologist are about half that of a white patient with the same skin condition, according to a new study in JAMA Dermatology. Patie
- XBiotech Adds Dr. Alice Gottlieb to its Scientific Advisory Boardhttps://practicaldermatology.com/news/xbiotech-adds-dr-alice-gottlieb-to-its-scientific-advisory-board/2457599/Alice Gottlieb, MD, PhD joined XBiotech Inc.'s Scientific Advisory Board (SAB). Dr. Alice Gottlieb is internationally recognized for her expertise and pioneering work in the development of biological therapies to treat skin diseases. Dr. Gottlieb has played key roles in the clinical eval
- FDA Green Lights First Spray-on-Skin Product for Burnshttps://practicaldermatology.com/news/fda-green-lights-first-spray-on-skin-product-for-burns/2457598/The US Food and Drug Administration granted premarket approval to Avita Medical’s Recell, a spray-on-skin that treats second- and third-degree burns in patients aged older than 18 years. The U.S. market launch for the Recell Autologous Cell Harvesting Device (RECELL® System) is
- Kuleana Debuts Natural, Reef-Safe Sunscreenhttps://practicaldermatology.com/news/kuleana-debuts-natural-reef-safe-sunscreen/2457601/Amid growing concerns that certain sunscreen ingredients are harming coral reefs and marine life, Hawaiian company Kuleana is rolling out a natural sunscreen that is free from oxybenzone and octinoxate – two chemicals known to be toxic to corals and other marine life that were recently bann
- Neova Launches New Line of Professional Grade Peelshttps://practicaldermatology.com/news/neova-launches-new-line-of-professional-grade-peels/2457604/Neova SmartSkinCare has introduced a new range of Professional Treatments developed exclusively for dermatologist use. The line of five new exfoliating peels integrate the newest and most advanced formulas with proven, established ingredients to produce visible results with minimal irritation and
- FDA Clears Sebacia Microparticles for Laser-Based Acne Treatmenthttps://practicaldermatology.com/news/fda-clears-sebacia-microparticles-for-laser-based-acne-treatment/2457603/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic
- Almirall and Evotec Form Dermatology Research Collaborationhttps://practicaldermatology.com/news/almirall-and-evotec-form-dermatology-research-collaboration/2457607/Alrimal and Evotec aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The two companies have for
- UCB: Study Data for Cimzia and Bimekizumab Presented at EADVhttps://practicaldermatology.com/news/ucb-data-for-cimzia-and-at-eadv/2457606/UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along with findings from an international survey on physicians’ perceptions about treating women wit